Filter Results:
(314)
Show Results For
- All HBS Web (540)
- Faculty Publications (111)
Show Results For
- All HBS Web (540)
- Faculty Publications (111)
Sort by
- 16 Jan 2013
- Research & Ideas
The Messy Link Between Slave Owners and Modern Management
management today. “How much more do we need to think about our responsibility to people?” As fascinating as her findings were, Rosenthal had some misgivings about their implications. She didn't want to be perceived as saying something... View Details
Keywords: by Katie Johnston
- 24 Oct 2007
- Sharpening Your Skills
Sharpening Your Skills: Managing Innovation
innovative solutions? Can Innovation And Creativity Be Managed? High Note: Managing the Medici String Quartet Many managers in business experience difficulty dealing with their best creative thinkers. So how... View Details
- July 2013 (Revised November 2021)
- Module Note
Exploration vs. Exploitation
By: Willy Shih
This module note introduces James March's concept of exploration and exploitation, and the management challenge of balancing the allocation of resources to the two activities in the firm. The note also touches on the O'Reilly and Tushman paper on the ambidextrous... View Details
Keywords: Exploration And Exploitation; Exploitation; Research; Scientific Research; Product Commercialization; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Knowledge Acquisition; Growth and Development Strategy; Resource Allocation; Strategic Planning; Research and Development; Science-Based Business; Corporate Strategy; Knowledge Sharing; Biotechnology Industry; Information Technology Industry; Manufacturing Industry; Medical Devices and Supplies Industry; Pharmaceutical Industry; Semiconductor Industry; Technology Industry; United States
Shih, Willy. "Exploration vs. Exploitation." Harvard Business School Module Note 614-004, July 2013. (Revised November 2021.)
- Research Summary
Clinical Trials as a setting for Health Policy and Management Research
The clinical trial marketplace is in flux. A decade ago, pharmaceutical firms almost exclusively conducted the study of their novel drug compounds within major academic medical centers. But today, industry-sponsored clinical trials are increasingly using community... View Details
- 06 Oct 2020
- Sharpening Your Skills
18 Tips Managers Can Use to Lead Through COVID's Rising Waters
Since March, Harvard Business School Working Knowledge has posted more than 80 stories and research papers on the topic of COVID-19, most targeted at managers and the new challenges they face. That's a lot of information to digest. To... View Details
Keywords: by Sean Silverthorne
- 29 Sep 2003
- Research & Ideas
Why Managing Innovation is Like Theater
If you don't know where you're going, any map will do.1 This conventional wisdom sounds right to many managers. It highlights the safety of having a clear objective for your management actions. It implies that all View Details
Keywords: by Rob Austin & Lee Devin
- November 2024
- Teaching Note
Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams
By: Debora L. Spar and Julia M. Comeau
Teaching Note for HBS Case No. 323-039. In 1990, satellite expert and Sirius XM founder Martine Rothblatt was determined to save the life of her seven-year-old daughter, Jenesis, who was diagnosed with a terminal illness called Pulmonary Arterial Hypertension (PAH). At... View Details
Keywords: Pharmaceutical Companies; Technological And Scientific Innovation; Organ Donation; Health Care and Treatment; Health Disorders; Innovation and Invention; Growth and Development Strategy; Product Development; Pharmaceutical Industry; Medical Devices and Supplies Industry; United States; District of Columbia
- March 2021
- Article
Increasing the Level of Abstraction as a Strategy for Accelerating the Adoption of Complex Technologies
By: Willy C. Shih
Many new technologies are complex and embody high levels of technical sophistication, and applying them should require significant knowledge and experience. Yet, the rapid adoption and incorporation of these technologies into other innovations seems inconsistent with... View Details
Keywords: Abstraction; Technological And Scientific Innovation; Technological Progress; Diffusion Of Innovation; Technology Adoption; Technological Innovation; Complexity; Information Technology; Strategy
Shih, Willy C. "Increasing the Level of Abstraction as a Strategy for Accelerating the Adoption of Complex Technologies." Strategy Science 6, no. 1 (March 2021): 54–61. (ISSN 2333-2050 (print), ISSN 2333-2077 (online))
- April 2014
- Case
Merrimack Pharmaceuticals, Inc. (A)
By: Amy C. Edmondson, Bethany S. Gerstein and Melissa Valentine
In 2006, Merrimack Pharmaceuticals was a fast-growing biotechnology company. Its leadership team was divided over whether to keep R&D organized in functional departments or transition to interdisciplinary teams. As a small company, Merrimack's R&D organization had... View Details
Keywords: Teamwork; Interdisciplinary Collaboration; R＆D; Biotechnology; Complexity; Innovation Management; Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Biotechnology Industry; Pharmaceutical Industry
Edmondson, Amy C., Bethany S. Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (A)." Harvard Business School Case 614-063, April 2014.
- April 2012
- Case
Danish National Advanced Technology Foundation
By: Willy Shih and Margaret Pierson
Danish National Advanced Technology Foundation (DNATF), a government agency, invests in public-private partnerships to stimulate commercialization of Danish scientific research within the country's industry. DNATF established a process for evaluating proposals, making... View Details
Keywords: Leadership; Commercialization; Management Practices and Processes; Experience and Expertise; Innovation and Invention; Public Ownership; Business and Government Relations; Technology Industry; Denmark
Shih, Willy, and Margaret Pierson. "Danish National Advanced Technology Foundation." Harvard Business School Case 612-091, April 2012.
- 13 Sep 2021
- Research & Ideas
Science: The Unlikely Frontier for New Business Ideas
through the red tape of academia to negotiate with an institution’s technology licensing department. Knowing where to look for the most interesting scientific advancements and how to filter for reliable studies isn’t every manager’s... View Details
Keywords: by Avery Forman
- December 1993 (Revised November 2009)
- Case
Manville Corporation Fiber Glass Group (A)
By: Lynn S. Paine and Sarah Gant
Manville Corp.'s senior managers must decide how to respond to a new scientific study suggesting that fiberglass, the source of 75% of the company's profits, may be another asbestos and must act under conditions of great uncertainty. In particular, when should a... View Details
Keywords: Communication Strategy; Decision Choices and Conditions; Ethics; Health Disorders; Risk Management; Marketing Communications; Product; Corporate Social Responsibility and Impact; Safety; Consumer Products Industry; Industrial Products Industry
Paine, Lynn S., and Sarah Gant. "Manville Corporation Fiber Glass Group (A)." Harvard Business School Case 394-117, December 1993. (Revised November 2009.)
- November 2001 (Revised September 2004)
- Case
Evolution of Treatment, The: The Case of Diabetes
By: Richard M.J. Bohmer, Jeffrey D. Street and Laura Feldman
Scientific knowledge surrounding diabetes mellitus has grown over the last century to include its cause, treatment, and prevention strategies. However, the type and level of care that patients receive is suboptional. This case examines the forces in industry,... View Details
Keywords: Policy; Health Care and Treatment; Innovation and Management; Knowledge Use and Leverage; Management; Management Analysis, Tools, and Techniques; Health Industry
Bohmer, Richard M.J., Jeffrey D. Street, and Laura Feldman. "Evolution of Treatment, The: The Case of Diabetes." Harvard Business School Case 302-023, November 2001. (Revised September 2004.)
- January 1997 (Revised September 1997)
- Case
Improving the Product Development Process at Kirkham Instruments Corp.
By: Clayton M. Christensen
Describes the efforts of a manufacturer of scientific instruments to implement new methods of managing new product development, which its executives had learned in a Harvard Business School seminar. The executives left the seminar excited to implement a new way of... View Details
Keywords: Change Management; Product Launch; Innovation and Invention; Product Development; Manufacturing Industry; Technology Industry; United States
Christensen, Clayton M. "Improving the Product Development Process at Kirkham Instruments Corp." Harvard Business School Case 697-058, January 1997. (Revised September 1997.)
- March 2019 (Revised July 2021)
- Case
Waymo LLC
By: John R. Wells and Benjamin Weinstock
On December 5, 2018, Waymo LLC, a subsidiary of Alphabet Inc., launched the United States’ first commercial driverless-car ride-hailing service (Waymo One), based in Phoenix, Arizona. As with other ride-hailing services such as Uber and Lyft, Waymo One riders... View Details
Keywords: Vehicle; Automation; Automobiles; Automotive; Driverless Car; Automotive Industry; Autonomy; Google; Self-driving Cars; Technological And Scientific Innovation; Technological Change; Technology Change; Ride-sharing; Uber; Lyft; General Motors; Innovation; Disruptive Technology; Disruptive Technologies; Tesla; Waymo; Operating Systems; Artificial Intelligence; Autonomous Vehicles; Transportation; Technological Innovation; Disruption; Commercialization; Growth and Development Strategy; Transportation Industry; Auto Industry
Wells, John R., and Benjamin Weinstock. "Waymo LLC." Harvard Business School Case 719-477, March 2019. (Revised July 2021.)
- 29 May 2013
- Research & Ideas
Faculty Symposium Showcases Breadth of Research
going on at the School. This year the presentation topics included the human tendency toward dishonesty, the use of crowdsourcing to solve major scientific problems, and the impact of private equity investments. Understanding Dishonesty... View Details
- 2015
- Book
How Culture Shapes the Climate Change Debate
By: Andrew J. Hoffman
Though the scientific community largely agrees that climate change is underway, debates about this issue remain fiercely polarized. These conversations have become a rhetorical contest, one where opposing sides try to achieve victory through playing on fear, distrust,... View Details
Hoffman, Andrew J. How Culture Shapes the Climate Change Debate. Stanford University Press, 2015. (Winner of the 2019 Responsible Research in Business Management Award; Honorable Mention for the 2016 Best Book Award, Organizations and Natural Environment Division, Academy of Management. Czech Edition: Jak kultura utváří diskusi o klimatické změně, Muni Press, 2017.)
- October 2016
- Article
Looking Across and Looking Beyond the Knowledge Frontier: Intellectual Distance and Resource Allocation in Science
By: Kevin J. Boudreau, Eva Guinan, Karim R. Lakhani and Christoph Riedl
Selecting among alternative innovative projects is a core management task in all innovating organizations. In this paper, we focus on the evaluation of frontier scientific research projects. We argue that the "intellectual distance" between the knowledge embodied in... View Details
Keywords: Knowledge; Innovation; Novelty; Evaluation; Resource Allocation; Decision Choices and Conditions; Innovation and Management; Science-Based Business; Experience and Expertise
Boudreau, Kevin J., Eva Guinan, Karim R. Lakhani, and Christoph Riedl. "Looking Across and Looking Beyond the Knowledge Frontier: Intellectual Distance and Resource Allocation in Science." Management Science 62, no. 10 (October 2016).
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and... View Details
Keywords: Health Care and Treatment; Strategic Planning; Competition; Patents; Innovation and Invention; Pharmaceutical Industry; Biotechnology Industry; United States
Oberholzer-Gee, Felix, and Dennis A. Yao. "Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug." Harvard Business School Case 706-454, December 2005. (Revised August 2006.)
- 20 Nov 2006
- Research & Ideas
Open Source Science: A New Model for Innovation
scientific problem solving? Yes, and it comes from an unexpected and unrelated corner of the universe: open source software development. That's the view of Karim R. Lakhani, an assistant professor at Harvard Business School with an... View Details
Keywords: by Martha Lagace